Verici Dx plans to launch TranscripTx, a first-in-class genetic test for transplant patients, in the fourth quarter of 2026.

The transplant diagnostics developer has been certified as an Olink Service Provider under Thermo Fisher's Life Sciences Solutions, adding a revenue-generating capability alongside its own biomarker pipeline.

The transplant diagnostics company reported $2.9m in recognised revenue from its Tutivia kidney rejection test in 2025, with Q1 volumes already running 32% ahead of the prior quarter.

The AIM-listed transplant diagnostics developer has secured New York State approval for its Tutivia kidney rejection test, completing authorisation across all 50 US states.

Verici Dx will offer up to £200,000 of new shares to UK retail investors via Winterflood's WRAP platform at 0.35p a share, following a placing that raised approximately £2.5m.

The company will raise gross proceeds of about £2.5m via an accelerated placing at 0.35p to fund the commercial scale‑up of its next‑generation kidney transplant blood tests, with a parallel WRAP retail offer to raise up to £0.2m.

A health economic analysis published in a peer‑reviewed journal estimates Verici Dx plc's Pre‑Transplant Risk Assessment (PTRA) test could deliver more than $191 million in healthcare savings across the US standard‑risk kidney transplant population over two years.